These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 31199173)

  • 1. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A; Muser E
    J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.
    Teeple A; Fitzgerald T
    J Dermatolog Treat; 2022 Feb; 33(1):518-524. PubMed ID: 32479140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    Imafuku S; Nakano A; Dakeshita H; Li J; Betts KA; Guerin A
    J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
    Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany.
    Augustin M; Wirth D; Mahlich J; Pepper AN; Druchok C
    J Dermatolog Treat; 2022 Mar; 33(2):976-982. PubMed ID: 32663067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
    Gordon KB; Armstrong AW; Han C; Foley P; Song M; Wasfi Y; You Y; Shen YK; Reich K
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
    Puig L; Wu JJ; Gooderham MJ; You Y; Shen YK; Randazzo B; Kerdel F
    J Dermatolog Treat; 2021 Aug; 32(5):484-491. PubMed ID: 31613178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.
    Reich K; Foley P; Han C; McElligott S; Muser E; Li N; Armstrong AW
    J Dermatolog Treat; 2020 Sep; 31(6):617-623. PubMed ID: 31305186
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis:
    Youn SW; Yu DY; Kim TY; Kim BS; Lee SC; Lee JH; Choe YB; Lee JH; Choi JH; Roh JY; Jo SJ; Lee ES; Shin MK; Lee MG; Jiang J; Lee Y
    J Dermatolog Treat; 2022 Feb; 33(1):535-541. PubMed ID: 32419536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
    Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
    J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods.
    Lasalvia P; Gil-Rojas Y; Papadimitropoulos E; Burge R; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):511-517. PubMed ID: 36927221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2019 Jun; 15(6):589-597. PubMed ID: 30920855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.